<DOC>
	<DOCNO>NCT00788567</DOCNO>
	<brief_summary>This study compare efficacy safety 2 dosing regimen oral CellCept administer component standard immunosuppressive therapy recipient kidney transplant . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>CLEAR Study - A Study CellCept ( Mycophenolate Mofetil ) Recipients Kidney Transplants</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>adult patient &gt; =18 year age ; recipient primary kidney transplant . positive HIV1 , human Tcell leukemia/lymphoma virus1 ( HTLV1 ) , hepatitis B surface antigen ; positive hepatitis C virus , moderate severe liver disease ; active malignancy history malignancy , exclude skin cancer ( basal squamous cell ) adequately treat ; need maintenance corticosteroid another condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>